{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"65","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"A patient will be considered an ocular-salvage success if enucleation because of disease progression or toxicity is not required during the 2 years following enrollment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive 1 intra-arterial injection (IA) of melphalan every 21- 30 days. Injections may be repeated every 21-30 days (up to a maximum of 3 cycles) assuming the patients meets the criteria to begin the next cycle.","id":"OG000","title":"Melphalan"}],"paramType":"NUMBER","populationDescription":"One patient who did not receive protocol therapy was excluded. Two patients who were lost to follow-up or follow-up was terminated electively prior to 2 years by patient or parent preference were excluded.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Probability of Ocular Salvage","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}